French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
ADVERTISEMENT
Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
John Mattick has been appointed to the Board of Directors of Oxford-based research company Arctoris Ltd.
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
GHO Capital raises €975m in largest ever European private equity healthcare fund.
Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.